Daxor Corporation Announces a 23 Percent Rise in BVA-100 Kit Sales in the Area of Cardiology and Filing of Form N-CSR for Jun...
August 24 2018 - 8:30AM
Daxor Corporation
(NYSE MKT: DXR) an investment
company with innovative medical instrumentation and biotechnology
operations filed a Form N-CSR disclosing its schedule of portfolio
holdings as of June 30, 2018.
In reporting its mid-year results, Daxor
Corporation has seen important developments in 2018 including a 23
percent rise in kit sales related to the use of its diagnostic
device, the BVA-100 blood volume analyzer in the area of
cardiology, which was driven by important data showing a
substantial benefit using the BVA-100 in a study of 245 patients
with hospitalized heart failure, Further, data was presented by
investigators at the Mayo Clinic during the 2018 American College
of Cardiology annual scientific meeting showing a 56 percent
reduction in hospital readmissions and 82 percent reduction in
mortality for patients measured on a 30-day basis when the BVA-100
test was used to guide treatment compared to a sampled control
group. These findings led to a surge in Daxor’s share price,
reaching a multi-year high of over $21 per share and driving not
only significant investor interest, but interest from numerous
researchers and clinicians in the use of the device.
Michael Feldschuh, CEO of Daxor said, “Sales
continue to excel driven by the combination of breakthrough outcome
studies like the recent data from the Mayo Clinic, focused
commercialization efforts and working with a number of researchers
and partners. With the strong trend in healthcare towards
individualized care and cost-effectiveness, we believe we are well
positioned to improve patient outcomes and guide better utilization
of hospital resources through the use of direct blood volume
analysis.”
Daxor continues to invest in further research
and development and has an active program focused on the next
generation of products. The company has filed new patents relating
to its key technology of blood volume measurement and has a
pipeline that is set for further innovations in 2018.
Copies of the N-CSR form will be mailed to the
Company’s shareholders and are filed with the SEC as well as on the
Company’s website at www.daxor.com.
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the first instrument approved by the
FDA to provide rapid direct measurement of a patient’s blood
volume. We believe that the BVA-100 Blood Volume Analyzer has the
potential to transform therapy in a broad range of surgical and
medical conditions. It is our goal, working in conjunction with
hospitals and clinics, to achieve that possibility. Ultimately the
company’s mission is to help hospitals and physicians incorporate
Daxor’s BVA-100 diagnostic to significantly improve the quality of
patient care. For more information please visit our website at
http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Daxor Corporation:
Soren Thompson
Investor Relations
212-330-8502
sthompson@daxor.com
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner
CORE IR
561-479-8566
brets@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
juleas@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024